As they deliver triglyceride to tissues, the particles shrink to 18–30 nm, transitioning into LDL with cholesterol as the dominant lipid. Structural changes in apoB-100 enhance its binding to ...
non-HDL cholesterol (HDL-C) is a secondary target of therapy after the LDL-C goal has been achieved. Non-HDL-C concentration is highly correlated, but may be discordant with that of ApoB.
When patients are found to have elevated non-HDL cholesterol, ApoB-100 or LDL particle concentrations, they are presumed to be at increased risk and are often prescribed more aggressive lipid ...